United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$311.04 USD
-6.01 (-1.90%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $311.08 +0.04 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
UTHR 311.04 -6.01(-1.90%)
Will UTHR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UTHR
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Other News for UTHR
Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
United Therapeutics Shareholders Show Strong Support at Annual Meeting
United Therapeutics (UTHR) Gets a Buy from Oppenheimer